Being a highly innovative company isn't a sufficient condition for success in the biotech industry. Bluebird Bio (NASDAQ: BLUE), a small-cap gene-editing specialist, is a good example of this. Though the company has developed groundbreaking therapies, the stock has significantly lagged the market in ...
motleyfoolusx:blue
